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OBJECTIVES The goal of our study was to determine whether hormone therapy alters markers of
inflammation in postmenopausal women with chronic stable coronary artery disease (CAD)
on appropriate medical management.
BACKGROUND Hormone therapy reduces some markers of inflammation associated with atherosclerosis risk
(cell adhesion molecules) but increases levels of another marker of inflammation—C-reactive
protein—in healthy postmenopausal women.
METHODS Ten women (average age 66 years; range 59 to 76 years) with CAD on medical management
(including aspirin [9], statin lipid-lowering therapy [7], angiotensin-converting enzyme
inhibitors [3]) were randomly assigned to conjugated equine estrogens 0.625 mg (combined
with medroxyprogesterone acetate 2.5 mg daily in five women with uterus intact) or
placebo(s) daily for one month with crossover to the alternate therapy after one month off of
hormone treatment in a double-blind study. At the end of each treatment phase, the
following markers of inflammation were measured in serum: interleukin-6, C-reactive
protein, E-selectin, intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and
matrix metalloproteinase-9.
RESULTS Hormone therapy significantly lowered serum levels of cell adhesion molecules E-selectin
(46.9 6 18.3 vs. 56.3 6 20.6 ng/mL, p 5 0.006), intercellular adhesion molecule-1 (282 6
74 vs. 304 6 78 ng/mL, p 5 0.013) and vascular cell adhesion molecule-1 (605 6 218 vs.
657 6 214 ng/mL, p 5 0.01) but increased levels of matrix metalloproteinase-9 (648 6 349
vs. 501 6 285 ng/mL, p 5 0.02). Interleukin-6 (4.33 6 4.78 vs. 3.04 6 1.47 pg/mL, p 5
0.283) and C-reactive protein (0.88 6 1.13 vs. 0.61 6 0.50 mg/dL, p 5 0.358) were not
significantly elevated on hormone therapy compared with placebo values.
CONCLUSIONS Hormone therapy has divergent effects on serum markers of inflammation in women with
CAD. Reduction in levels of cell adhesion molecules may reduce attachment of white blood
cells to the vessel wall, but increases in matrix metalloproteinase-9 within the vessel wall could
digest and weaken fibrous caps of vulnerable plaques, thus provoking thrombosis. (J Am Coll
Cardiol 2000;36:1797–802) © 2000 by the American College of Cardiology
Hormone therapy has been associated with reduced risk of
coronary heart disease events in observational studies of
healthy postmenopausal women (1). Although favorable
effects of estrogen therapy on lipoproteins may account for
much of this apparent benefit, direct vascular effects may
also be of importance, including increased nitric oxide
bioactivity, enhanced fibrinolysis and reduction in levels of
soluble cell adhesion molecules (2–4). However, levels of
C-reactive protein (CRP) are increased with hormone
therapy in healthy postmenopausal women suggesting that
estrogen may initiate or aggravate inflammation (5–8) that
in some women could contribute to the progression and
clinical expression of atherosclerosis.
The Heart and Estrogen/progestin Replacement Study
(HERS) is the first randomized, double-blind, placebo-
controlled clinical trial testing the potential cardiovascular
benefit of hormone therapy to be completed in postmeno-
pausal women (9). This secondary prevention trial random-
ized 2,763 postmenopausal women with coronary artery
disease (CAD) to conjugated equine estrogens (CEE)
0.625 mg combined with medroxyprogesterone acetate
(MPA) 2.5 mg daily, or placebo daily, in addition to
conventional management. After an average follow-up of
4.1 years, there were no significant differences between
hormone therapy and placebo treatment groups in the
primary outcomes of nonfatal myocardial infarction (MI)
and coronary heart disease death. However, there was a
statistically significant time-trend of more coronary heart
disease events—especially MI—in the hormone therapy
group than there was in the placebo group during the first
year after randomization, but there were fewer events in
years 4 and 5 of treatment. In a preliminary report of 2,245
postmenopausal women in the Nurses’ Health Study cohort
with CAD, a two-fold increased risk of MI or coronary
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heart disease death was observed within the first year after
initiation of hormone therapy in women with prior MI
compared with nonusers of hormones (10). Almost 30 years
ago a similar observation was made in the Coronary Drug
Project of men with previous MI; those men randomized to
CEE therapy had a significantly increased MI event rate
early after randomization, resulting in early termination of
the CEE 5 mg treatment arm of the clinical trial (11).
Pathological studies have shown that MI is commonly
associated with rupture of the fibrous caps of atherosclerotic
plaques, exposing the thrombogenic lipid-rich contents of
the plaque to blood (12–14). Inflammatory cells and acti-
vated smooth muscle cells commonly associated with ath-
eromatous plaques secrete matrix metalloproteinases
(MMP) (15). After activation by plasmin and other en-
zymes, MMPs may digest the matrix proteins of the fibrous
cap, thus weakening the cap and predisposing it to rupture
with thrombus formation (16). In this regard, increased
expression of enzymatically active MMPs has been detected
in human atherosclerotic plaques (17–19). Further, in-
creased levels of MMP-2 (gelatinase A) and MMP-9
(gelatinase B) in serum have been reported in CAD patients
with unstable angina or acute MI (20).
Because hormone therapy has been associated with in-
creased levels of CRP in healthy postmenopausal women,
which could indicate activation of inflammatory cells, this
study was designed to assess the effect of hormone therapy
on markers of inflammation, including MMP expression, in
postmenopausal women with CAD who were on appropri-
ate medical management.
METHODS
Ten women (average age 66 years; range 59 to 76 years)
with angiographically documented CAD (.70% stenosis of
at least 1 coronary artery at the time of diagnostic cardiac
catheterization) and left ventricular ejection fractions $40%
were enrolled in this study. All patients were Canadian
Cardiovascular Society functional class I or II and remained
on medical management (including aspirin [9], statin lipid-
lowering drugs [7], calcium channel blocking agent [5],
beta-adrenergic blocking agents [5], angiotensin-converting
enzyme inhibitors [3] and chronic nitrates [1]) during the
entire study. Two women were treated with oral hypogly-
cemic drugs for adult-onset diabetes mellitus. In this
double-blind study, patients were randomized to CEE
0.625 mg daily (combined with MPA 2.5 mg daily in five
women with uterus intact) or identical placebo(s) daily, each
for one month, with one month off of investigational
therapy before crossover to the alternate therapy. This
protocol was approved by the Institutional Review Board of
the National Heart, Lung and Blood Institute, and in-
formed written consent was obtained from all study partic-
ipants.
Laboratory assays. Blood samples for laboratory assays
were obtained between 8 and 9 AM after overnight fasting
and approximately 1 h after taking morning medications
and study drugs. Samples were immediately coded so that
investigators performing laboratory assays were blinded to
subject identity and study sequence. Estrone and 17b-
estradiol levels were measured in serum by radioimmuno-
assay in order to determine compliance with study drugs.
Total cholesterol and glycerol-blanked triglycerides in the
serum were quantified by automated enzymatic techniques.
Serum high-density lipoprotein cholesterol was quantified
after dextran sulfate precipitation of other lipoproteins.
Serum low-density lipoprotein cholesterol levels were di-
rectly quantified by an immunoabsorption method. The
following markers of inflammation were measured in serum
in batches with duplicate samples: CRP (two site chemilu-
minesent enzyme immunometric assay, sensitivity:
0.01 mg/dL; Immulite, DPC, Los Angeles, California),
interleukin-6 (IL-6; ELISA; R&D Systems, Minneapolis,
Minnesota) and the cell adhesion molecules E-selectin,
intercellular adhesion molecule-1 (ICAM-1) and vascular
cell adhesion molecule-1 (VCAM-1) (ELISA; R&D Sys-
tems, Inc., Minneapolis, Minnesota). Plasminogen activator
inhibitor-1 (PAI-1) antigen levels in plasma were deter-
mined by sandwich ELISA assay (Biopool, Ventura, Cali-
fornia).
Total MMP-9 (gelatinase B; proenzyme and active en-
zyme bound to inhibitor) was measured in serum with
duplicate samples by sandwich ELISA (Quantikine, R&D
Systems, Minneapolis, Minnesota). Plasma samples were
collected in EDTA tubes (necessary for PAI-1 determina-
tion) and, thus, could not be assayed for MMP because of
interference by EDTA with the assay. Additionally,
MMP-2 and MMP-9 were analyzed by zymography, with
determination of the digestion of gelatin in polyacrylamide
gels by serum samples, as previously described (21). Serum
aliquots (0.5 mL for MMP-2 and 1.0 mL for MMP-9) were
added to 10 mL loading buffer and loaded on 10% poly-
acrylamide gels (Novex) containing 0.1% gelatin. After
electrophoresis, gels were incubated in 0.05 mmol/L Tris-
HCl, pH 7.5, containing 0.2 mol/L NaCl, 5 mmol/L CaCl2
and 2.5% Triton X-100, for 30 to 60 min at room
temperature and subsequently incubated for 16 h at 37°C in
the same buffer without Triton X-100. The gels were then
stained with Coomassie blue (0.25% Coomassie blue/45.4%
Abbreviations and Acronyms
AP-1 5 activator protein-1
CAD 5 coronary artery disease
CEE 5 conjugated equine estrogens
CRP 5 C-reactive protein
ICAM-1 5 intercellular adhesion molecule-1
IL-6 5 interleukin-6
MI 5 myocardial infarction
MMP 5 matrix metalloproteinases
MPA 5 medroxyprogesterone acetate
PAI-1 5 plasminogen activator inhibitor-1
VCAM-1 5 vascular cell adhesion molecule-1
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methanol/9.2% glacial acetic acid) and destained (75%
ethanol/25% glacial acetic acid). Clear zones against the
blue background indicated the presence of proteolytic activ-
ity. Renaturation of MMP-2 and MMP-9 with Triton
X-100 allows both latent and active forms to be detected.
The zymography gels were scanned by a ScanMaker 5
(Microtek International, Inc., Hsinchu, Taiwan) using
Adobe Photoshop (Adobe Systems Inc., Mountain View,
California). Bands on the scan were analyzed by the
Macintosh version of Image, and the relative densitometric
areas were calculated by integrating the area under each
peak. Areas are expressed as arbitrary units.
Statistical analysis. Data are expressed as means 6 stan-
dard deviation. After testing for normality, Student paired t
test (E-selectin, ICAM-1, VCAM-1, MMP-9, PAI-1) or
Wilcoxon signed rank test (CRP, IL-6) was used to
compare values before and after each therapy. Pearson
correlation coefficient analysis was used to assess associa-
tions between measured parameters. p values ,0.05 were
accepted as statistically significant.
RESULTS
Compliance with study medications was excellent, as man-
ifested by increases in serum estrone and 17b-estradiol
levels in all women during the hormone treatment phase of
the study (Table 1). Hormone replacement therapy lowered
levels of total cholesterol and low-density lipoprotein cho-
lesterol by approximately 10% and increased levels of high-
density lipoprotein cholesterol and apolipoprotein (A-1)
each by approximately 10%. Triglycerides were unchanged
with hormone therapy compared with placebo values.
Assay values for markers of inflammation are provided in
Table 2. C-reactive protein and IL-6 values in patients on
placebo were highly correlated (r 5 0.928, p , 0.001).
However, there was no correlation between levels of
MMP-9 and CRP (r 5 0.135, p 5 0.710) or IL-6 (r 5
0.207, p 5 0.566) on placebo. Hormone therapy did not
significantly increase levels of CRP and IL-6 in serum but
significantly lowered PAI-1 levels in plasma compared with
placebo values. Hormone therapy significantly reduced lev-
els of the cell adhesion molecules E-selectin, ICAM-1 and
VCAM-1 (Fig. 1), with similar magnitude of reduction
from placebo values in women on CEE alone compared
with women on combination hormone therapy (E-selectin
20% vs. 13%, ICAM-1 7% vs. 7%; VCAM-1 8% vs. 9%).
Hormone therapy significantly increased serum MMP-9
compared with placebo (Table 2), with higher levels of
MMP-9 in 9 of 10 women compared with respective
placebo values (Fig. 2). Increases in MMP-9 levels on
hormone therapy appeared to be similar in women on CEE
alone compared with women on combination hormone
therapy. There was no correlation between the placebo
MMP-9 levels and the increase in MMP-9 on hormone
therapy relative to placebo (r 5 0.492, p 5 0.149). The only
patient (D) who had lower levels of MMP-9 on hormone
therapy had increases in CRP (0.77 to 1.03 mg/dL) and
IL-6 (2.67 to 3.45 pg/mL) compared with placebo values.
For the group, there was no correlation between the
increases in CRP and in MMP-9 on hormone therapy
relative to placebo (r 5 0.150, p 5 0.680) or the increases
Figure 1. Serum levels of the cell adhesion molecules E-selectin, intercel-
lular adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1) are shown for the 10 study participants during
placebo and hormone therapy (HT) treatment periods of the study.
CEE 5 conjugated equine estrogens; MPA 5 medroxyprogesterone
acetate.
Table 1. Effects of Hormone Therapy on Hormone and
Lipid Values
Placebo
Hormone
Therapy p Value
Hormones (pg/mL)
Estrone 22 6 17 98 6 59 , 0.001
17b-Estradiol 15 6 8 50 6 24 , 0.001
Lipids (mg/dL)
Total cholesterol 220 6 38 202 6 52 0.337
LDL cholesterol 133 6 32 121 6 50 0.364
Apolipoprotein B 121 6 24 119 6 39 0.863
HDL cholesterol 41 6 6 46 6 13 0.097
Apolipoprotein A-I 124 6 16 136 6 14 0.010
Triglycerides 249 6 275 215 6 146 0.622
HDL 5 high-density lipoprotein; LDL 5 low-density lipoprotein.
Table 2. Effects of Hormone Therapy on Markers of
Inflammation and MMP-9 Expression in Serum
Placebo
Hormone
Therapy p Value
Markers of inflammation
C-reactive protein (mg/dL) 0.61 6 0.50 0.88 6 1.13 0.358
Interleukin-6 (pg/mL) 3.04 6 1.47 4.33 6 4.78 0.283
E-selectin (ng/mL) 56.3 6 20.6 46.9 6 18.3 0.006
ICAM-1 (ng/mL) 304 6 78 282 6 74 0.013
VCAM-1 (ng/mL) 657 6 214 605 6 218 0.010
MMP-9 (ng/mL) 501 6 285 648 6 349 0.020
Gelatinolytic activity
(densitometric U)
1,250 6 644 1517 6 748 0.036
PAI-1 (ng/mL) 42.3 6 26.8 28.5 6 21.0 0.030
Data are expressed as mean 6 standard deviation.
ICAM-1 5 intercellular adhesion molecule-1; MMP-9 5 matrix metalloprotein-
ase-9; PAI-1 5 plasminogen activator inhibitor-1; VCAM-1 5 vascular cell adhesion
molecule-1.
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in IL-6 and in MMP-9 on hormone therapy relative to
placebo (r 5 20.246, p 50.494).
By zymography, proteolysis of gelatin by 92 kDa MMP-9
was greater in serum samples from the hormone therapy
phase relative to placebo (1,517 6 748 vs. 1,250 6 644
densitometric U, p 5 0.036), with greater gelatinolysis in 8
of 10 women on hormone therapy than on placebo (Fig. 3),
including eight of nine women who had higher serum
MMP-9 levels, as measured by ELISA on hormone therapy
compared with placebo values (Fig. 2).
By zymography, proteolysis of gelatin by the 72 kDa
MMP-2 was similar on placebo (956 6 228 densitometric
U) and hormone therapy (880 6 245 densitometric U), and
no patient had higher MMP-2 levels on hormone therapy
relative to placebo values.
DISCUSSION
We have previously reported that hormone replacement
therapy significantly reduces serum levels of cell adhesion
molecules in healthy postmenopausal women who were not
taking other medications at the time of their study (4). We
found in this study that hormone replacement therapy
significantly reduced levels of the three cell adhesion
molecules—E-selectin, ICAM-1, VCAM-1—measured in
our study relative to placebo values in women with CAD,
despite continued medical management with drugs previ-
ously shown to reduce cardiovascular risk (aspirin, statin
lipid-lowering therapy, angiotensin-converting enzyme in-
hibitors). Serum concentrations of cell adhesion molecules
have been reported to be higher for patients with CAD than
in healthy subjects (22). Although the biological function in
serum remains unclear, the clinical relevance of cell adhe-
sion molecules has been suggested by several observational
studies. Thus, E-selectin, ICAM-1 and VCAM-1 have
been demonstrated in human atherosclerotic arteries by
immunohistochemistry (23,24). In the Atherosclerosis Risk
in Communities (ARIC) study (25), higher serum levels of
E-selectin and ICAM-1 were found in patients with CAD
and carotid artery atherosclerosis than in healthy control
subjects; E-selectin levels correlated positively with the
carotid artery thickness measured by ultrasound in this
study. Rohde et al. (26) reported significant correlations
between ICAM-1 and VCAM-1 levels and carotid artery
intimal-medial thickness in 92 men and women referred to
their echocardiography laboratory. Men in the Physician’s
Health Study (27) with the highest quartile of ICAM-1
levels were found to be at greater cardiovascular risk than
men in the lowest quartile. Our findings are consistent with
the observation of Caulin-Glaser and coworkers (28) who
found higher serum levels of E-selectin, ICAM-1 and
VCAM-1 in postmenopausal women with CAD not on
hormone therapy than postmenopausal women with CAD
on hormone therapy at the time of cardiac catheterization.
Hormone therapy and MMP. In this study hormone
therapy increased serum levels of MMP-9 in women with
CAD, as determined by monoclonal antibody immunoassay
and by zymography. By these independent assays, the
majority of women had higher MMP-9 levels on hormone
therapy than on placebo, whether on CEE alone or on CEE
combined with MPA. This effect of hormone therapy was
seen despite continuation of medications shown to reduce
Figure 2. Matrix metalloproteinase-9 (MMP-9) serum levels by ELISA
are shown for the 10 study participants identified by letters A through J
(the order of entry into the study) and during placebo and hormone therapy
treatment phases of the study. CEE 5 conjugated equine estrogens;
MPA 5 medroxyprogesterone acetate.
Figure 3. Panel A: Zymography of paired serum samples from the 10
study participants with coronary artery disease shows digestion of gelatin at
the 92 kDa band, indicative of the proenzyme form of MMP-9, during
placebo (2) and hormone therapy (1) treatment periods of the study.
Individual patients are identified by letters A through J and correspond
with the identification letters in Figure 2. Panel B: Optical scanning of the
zymograms from panel A, with values reported as densitometric units.
Solid bars 5 placebo; open bars 5 estrogen. MMP 5 matrix metallo-
proteinase.
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cardiovascular risk for patients with CAD. Levels of CRP
and IL-6, nonspecific markers of inflammation associated
with atherosclerosis and increased cardiovascular risk (29–
33), were slightly increased on hormone therapy, consistent
with recent reports performed in healthy postmenopausal
women (5–8) suggesting that estrogen may have initiated or
aggravated inflammation in our study population with
CAD. Increased vascular inflammation could increase syn-
thesis of MMP-9 by inflammatory cells or activated smooth
muscle cells within the vessel wall. However, there was no
correlation between the relative increases in CRP or in IL-6
and in MMP-9 to support a proinflammatory effect of
estrogen as a stimulus for increased MMP-9 expression.
Mechanism of increased MMP-9 expression. The in-
crease in MMP-9 during hormone therapy is compatible
with direct enhancement of enzyme synthesis by estrogen.
Although classical estrogen response elements have not
been identified in the promoter regions of MMPs, several
MMPs, including MMP-9, have consensus sequences for
activator protein-1 (AP-1) sites (34–37). Estrogen bound to
its receptor (especially ERa [38]) activates transcription of
target genes under control of AP-1 response elements by
binding to the Jun-Fos heterodimer of AP-1, facilitating
activation of the AP-1 response element with enhanced
transcription (38–40). Of interest, MMP-2, which does not
have an AP-1 site in its promoter region, was not altered by
estrogen treatment in our study as measured by zymogra-
phy. In this regard our findings differ from the report of
Wingrove et al. (41) in which human vascular smooth
muscle cells in culture were found to increase the synthesis
of MMP-2 at physiological concentrations of 17b-estradiol.
Study limitations. A limitation of this study is that the
increase in serum levels of MMP-9 in our study participants
on hormone therapy does not prove increased enzymatic
MMP activity on matrix proteins within the atherosclerotic
plaque. Indeed, the MMP-9 measured by zymography in
our study was in the 92 kDa proenzyme form and likely
bound in serum to protein inhibitors (TIMP-1, a2-
macroglobulin). However, Galis et al. (17) have shown that
MMPs in human atherosclerotic plaques have gelatinase
activity, as assessed by in situ zymography, which suggests
that local synthesis of MMPs within the plaque may exceed
the local synthesis of inhibitor proteins.
Potential for metalloproteinase activation. Hormone
therapy in postmenopausal women may also provide a
mechanism for activation of MMPs in the vessel wall. We
have previously shown that hormone therapy reduces
plasma levels of PAI-1, a principal inhibitor of plasminogen
activators (3). This results in increased plasmin activity, as
evidenced by proportionate increases in serum levels of
D-dimer, the breakdown product of cross-linked fibrin
enzymatically digested by plasmin. Plasmin also activates
MMPs by converting the inactive zymogen form of the
enzyme to the active proteolytic form (42–44). Similar to
the effect of hormone therapy previously shown in healthy
postmenopausal women (40), plasma levels of PAI-1 were
reduced in women with CAD in this study. Accordingly,
the combination of increased expression of MMP-9 and the
potential for increased plasmin-mediated activation of
MMP-9 in women with vulnerable plaques could result in
the digestion of matrix proteins that comprise the fibrous
cap, with plaque rupture and thrombosis.
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